Impact of granting a Conditional Marketing Authorisation for Pfizer-BioNTech COVID-19 vaccine (Comirnaty®)

Document first published:
Page updated:
Topic:
,
Publication type:

This letter draws attention to a number of operational implications for the management of the Pfizer-BioNTech vaccines and asks for appropriate steps to be taken to make relevant colleagues aware.

Summary

Letter from Dr Keith Ridge CBE, Chief Pharmaceutical Officer for England.

Published 26 August 2021.